Xvivo Perfusion AB (publ) (STO:XVIVO)
281.00
+2.20 (0.79%)
Aug 26, 2026, 5:29 PM CET
Xvivo Perfusion AB Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Xvivo Perfusion AB stock has a consensus rating of "Strong Buy" and an average price target of kr 335.60. The average 1-year stock price forecast is 19.43% higher than the current stock price, while the lowest is kr 300.00 (+6.76%) and the highest is kr 385.00 (+37.01%).
Price Target: kr 335.60 (+19.43%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Xvivo Perfusion AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
989.58M
from 812.17M
Increased by 21.84%
Revenue Next Year
1.26B
from 989.58M
Increased by 27.38%
EPS This Year
3.50
from 0.85
Increased by 310.65%
EPS Next Year
6.22
from 3.50
Increased by 77.83%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.